Combination of Paclitaxel and PXR Antagonist SPA70 Reverses Paclitaxel-Resistant Non-Small Cell Lung Cancer

Paclitaxel (PTX) is one of the most efficient drugs for late-stage non-small cell lung cancer (NSCLC) patients. However, most patients gradually develop resistance to PTX with long-term treatments. The identification of new strategies to reverse PTX resistance in NSCLC is crucially important for the...

Descripción completa

Detalles Bibliográficos
Autores principales: Niu, Xiaxia, Wu, Ting, Yin, Qishuang, Gu, Xinsheng, Li, Gege, Zhou, Changlong, Ma, Mei, Su, Li, Tang, Shu, Tian, Yanan, Yang, Ming, Cui, Hongmei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563422/
https://www.ncbi.nlm.nih.gov/pubmed/36231056
http://dx.doi.org/10.3390/cells11193094

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563422/
https://www.ncbi.nlm.nih.gov/pubmed/36231056
http://dx.doi.org/10.3390/cells11193094

Ejemplares similares